Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas-Maxygen Joint Venture Highlights Japan's Creative Alliances - BIO Asia Conference

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Astellas, like most top-tier Japanese pharmaceutical companies, has been aggressive in its out-licensing in the past year, and its 2009 joint venture with Maxygen highlights how Japanese companies are using creative deals to stay competitive

You may also be interested in...



Astellas Increases R&D To Bridge Prograf, Flomax Patent Losses

Japan's second-largest drug maker Astellas estimates net profit is down by 27 percent to ¥125 billion ($1.375 billion) for fiscal year 2009, due largely to decreasing sales from patent losses in major products Prograf (tacrolimus) and Flomax (tamsulosin) and increasing research and development expenses to cultivate new products

Astellas Increases R&D To Bridge Prograf, Flomax Patent Losses

Japan's second-largest drug maker Astellas estimates net profit is down by 27 percent to ¥125 billion ($1.375 billion) for fiscal year 2009, due largely to decreasing sales from patent losses in major products Prograf (tacrolimus) and Flomax (tamsulosin) and increasing research and development expenses to cultivate new products

Astellas Signs Strategic Oncology Partnership With Ambit After Medivation Success

Just days after Takeda signed a strategic alliance with Seattle Genetics for oncology antibody drug development, Astellas announced Dec. 18 a worldwide agreement with San Diego-based Ambit Bioscience to jointly develop and commercialize FMS-like tyrosine kinase-3 inhibitors for multiple oncology and non-oncology indications

UsernamePublicRestriction

Register

CO180755

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel